Clinical and experimental rheumatology最新文献

{"title":"Seasonal shifts and population characteristics of uric acid in eastern coastal China: a big data analysis from Hangzhou.","authors":"Xi Chen, Jing Du, De-Li Ye, Jun Xia, Hua Zhang","doi":"10.55563/clinexprheumatol/eg8gtg","DOIUrl":"https://doi.org/10.55563/clinexprheumatol/eg8gtg","url":null,"abstract":"<p><strong>Objectives: </strong>Uric acid (UA), the end-product of purine metabolism, is linked to various medical conditions such as gout and cardiovascular diseases. The increasing incidence of hyperuricaemia and gout in China highlights the need to establish accurate reference intervals for UA. This study uses data from a real-world population to examine the distribution of UA levels across various demographic groups, with a specific focus on seasonal variations in UA concentrations. Through the application of an indirect statistical method, the research aims to establish more precise UA reference intervals for clinical use.</p><p><strong>Methods: </strong>We analysed 749,739 serum UA data from adults (≥18 years) over 2 years, 2021-2022, studying seasonal, gender, and age effects. The reference intervals were established via the indirect method, and the differences from the manufacturer's ranges were assessed using the reference change value (RCV).</p><p><strong>Results: </strong>UA levels showed seasonal variations with significant gender disparities. In winter/spring, males 18-44: 262-539 µmol/L, females: 175-385 µmol/L; males 45+: 243-525 µmol/L, females: 185-406 µmol/L. In summer/autumn, males 18-44: 273-552 µmol/L, females: 185-395 µmol/L; males 45+: 250-537 µmol/L, females: 192-410 µmol/L. A significant difference was observed in the reference range for males compared to the manufacturer's range, but no difference for females.</p><p><strong>Conclusions: </strong>Extensive data analysis has uncovered seasonal fluctuations and notable gender- and age-related effects on serum UA concentrations. Using the indirect method to establish more refined reference intervals for serum UA levels confers practical relevance in clinical practice.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144636286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Undifferentiated spondyloarthritis with late onset large vessel vasculitis and upadacitinib induced remission.","authors":"Nehaal Ahmed, Kenneth J Warrington, Matthew J Koster","doi":"10.55563/clinexprheumatol/8ocj7h","DOIUrl":"https://doi.org/10.55563/clinexprheumatol/8ocj7h","url":null,"abstract":"","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144636291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RANTES is a possible marker of paradoxical psoriatic arthritis.","authors":"En-Chih Liao, Yi-Da Wu, Shang-Hung Lin, Kuo-Lung Lai, Wei-Ting Chao, Chung-Yang Yen","doi":"10.55563/clinexprheumatol/ktbnx4","DOIUrl":"https://doi.org/10.55563/clinexprheumatol/ktbnx4","url":null,"abstract":"<p><strong>Objectives: </strong>Biologic therapies have revolutionised the treatment of psoriasis (PsO) and psoriatic arthritis (PsA), significantly improving patient outcomes. However, paradoxical psoriatic arthritis (PPsA), a condition where biologics exacerbate joint inflammation, has emerged as a rare but concerning adverse effect. This study aimed to investigate the immunological mechanisms underlying PPsA and identify potential biomarkers associated with its development.</p><p><strong>Methods: </strong>A cohort of 23 patients with PsO, with or without concurrent PsA, who had undergone biologic therapy, was analysed. Peripheral blood mononuclear cells (PBMCs) were isolated and stimulated with Streptococcus pyogenes to mimic inflammatory outbreaks, followed by ex vivo treatment with the biologics each patient had experienced. Cytokine and chemokine levels were quantified to assess immune responses.</p><p><strong>Results: </strong>Patients who developed PPsA exhibited a significant elevation in regulated upon activation normal T cell expressed and secreted (RANTES) levels (p = 0.001) after exposure to culprit biologics, compared to those without PPsA. Additionally, a notable decrease in interferon-gamma (IFN-γ) levels was observed, suggesting altered immune dynamics. These findings indicate that RANTES plays a central role in the pathogenesis of PPsA and may serve as a predictive biomarker.</p><p><strong>Conclusions: </strong>This study highlights the importance of screening for elevated RANTES levels before initiating biologic therapy to mitigate PPsA risk. The results underscore the need for personalised therapeutic approaches and further research into the molecular mechanisms of PPsA, paving the way for safer and more effective treatments.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144636282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of thrombotic events in patients with idiopathic inflammatory myopathies.","authors":"Sangmee Sharon Bae, Jennifer Wang, Ani Shahbazian, Daniela Markovic, Yuna Lee, Tiffany De Leon, David Elashoff, Christina Charles-Schoeman","doi":"10.55563/clinexprheumatol/bj7nq2","DOIUrl":"https://doi.org/10.55563/clinexprheumatol/bj7nq2","url":null,"abstract":"<p><strong>Objectives: </strong>To identify predictors of thrombotic events in patients with idiopathic inflammatory myopathies (IIM).</p><p><strong>Methods: </strong>We conducted a retrospective study of a large, longitudinal IIM cohort followed at a single academic centre. We used Poisson regression models to estimate incidence-rate ratios (IRR) of prospective arterial and venous thrombotic events (ATE and VTE respectively).</p><p><strong>Results: </strong>Thrombotic events occurred in 37 out of 312 patients (12%) over a median [interquartile range (IQR)] follow up time of 6[2-11] years after IIM diagnosis. Among patients with thrombotic events, 65% had VTE, which predominantly occurred within the first 3 years of IIM diagnosis, while 41% had ATE, which predominantly occurred after 10 years from IIM diagnosis. In predictive models, disease duration less than 1 year (IRR 6.49, 95%CI 1.89-22.35) was the strongest risk factor for VTE. Prior ATE was the strongest risk factor for prospective ATE (IRR 18.78, 95%CI 10.98-32.12). Traditional cardiovascular (CV) risk factors and higher levels of myositis activity and damage were other predictors of prospective ATE. The lactonase activity of PON1 was independent of the PON1 Q192R polymorphism and enhanced prediction of ATE in patients with high CV risk. IVIG was not associated with increased thrombotic risk in a high-risk population.</p><p><strong>Conclusions: </strong>We report the incidence and risk factors for thrombotic events in a single-centre longitudinal IIM cohort, showing early occurrence of VTE and late onset of ATE. PON1 activity was predictive of ATE in a high-risk subgroup of IIM patients.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144636281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of ultrasound in the interception of psoriatic arthritis in patients with psoriasis.","authors":"Niccolò Possemato, Alessandra Rai, Marianna Oliva, Nicolò Girolimetto, Carlo Salvarani, Antonio Marchesoni","doi":"10.55563/clinexprheumatol/vudu1q","DOIUrl":"https://doi.org/10.55563/clinexprheumatol/vudu1q","url":null,"abstract":"<p><p>Skin psoriasis (PsO) often precedes the development of psoriatic arthritis (PsA), with a PsO to PsA conversion rate of about 1.5-2% per year. A careful observation of the PsO patients may allow early detection, treatment, and maybe even prevention, of the rheumatic condition. In PsA patients, musculoskeletal ultrasound (MSK-US) imaging can be used to investigate the presence of enthesitis, synovitis, tenosynovitis, and paratenonitis and this imaging technique has been shown to be more sensitive than clinical examination. MSK-US may reveal the presence of synovial and entheseal inflammation even in PsO patients without musculoskeletal symptoms and these findings might be considered indicative of subclinical PsA, although a clinical evaluation is essential to prevent overdiagnosis and overtreatment. This narrative review provides an overview of the transition from PsO to PsA with a focus on the value of US examination in this context.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144636284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporal trends in overall infection incidence in patients with inflammatory arthritides treated with tumour necrosis factor inhibitors: a nationwide cohort study.","authors":"Aron Hjalti Bjornsson, Telma Thrastardottir, Bjorn Gudbjornsson, Thorvardur Jon Love","doi":"10.55563/clinexprheumatol/ijo29l","DOIUrl":"https://doi.org/10.55563/clinexprheumatol/ijo29l","url":null,"abstract":"<p><strong>Objectives: </strong>To investigate temporal trends in infection rates among patients with inflammatory arthritides receiving tumour necrosis factor inhibitors (TNFi) and explore whether the incidence of infections among patients starting TNFi treatment has changed with increasing access to TNFi.</p><p><strong>Methods: </strong>In this nationwide matched cohort study, we extracted information on all adult biologic-naive patients with rheumatoid arthritis, psoriatic arthritis, and spondyloarthritides initiating treatment with a TNFi from the ICEBIO registry. Each patient was randomly matched on age, sex, and calendar time to five general population comparators. Patients were observed for two years before and after TNFi initiation. All ICD-10 infection codes and information on filled prescriptions were extracted from nationwide registries. The data were split into four-year periods, and incidence rate (IR) per 1000 patient-years and IR ratios (IRR) of serious infections (SI) and prescriptions for each period were calculated.</p><p><strong>Results: </strong>We identified 1387 individuals initiating their first TNFi treatment in 2003-2018 and 6936 general population comparators. The between-period IRR for SI was 0.48 (0.25-0.94, p=0.03) for the TNFi-treated patients in the last period compared to the first, while it was 1.05 (0.93-1.2) for antimicrobial prescriptions. The IRR for comparators was stable for SI but increased for antimicrobial prescriptions (1.2 (1.1-1.3)).</p><p><strong>Conclusions: </strong>The study found that the IRR of serious infections associated with TNFi in patients with inflammatory arthritides has decreased over the years. The trend of diminishing SI incidence needs to be considered when analysing data over long periods or comparing recent research to previously published data.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144636287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retention rate and predictors of discontinuation for secukinumab treatment: real-life data in a cohort of patients with spondyloarthritis.","authors":"Elisa Bellis, Mariele Gatto, Gloria Crepaldi, Valeria Data, Claudia Lomater, Elena M Marucco, Silvia Perrone, Marta Saracco, Annamaria Iagnocco","doi":"10.55563/clinexprheumatol/cruuvo","DOIUrl":"https://doi.org/10.55563/clinexprheumatol/cruuvo","url":null,"abstract":"<p><strong>Objectives: </strong>This study evaluated the real-world retention rate and predictors of discontinuation for secukinumab therapy in patients with spondyloarthritis (SpA).</p><p><strong>Methods: </strong>This observational, retrospective cohort study included SpA patients treated with secukinumab at a referral centre. Baseline demographic and clinical data were recorded, covering comorbidities, prior biologic/targeted synthetic therapies, and disease duration. Secukinumab retention rates were analysed at 12 months and at the end of the study (last observation or discontinuation). Drug retention rate (DRR) was assessed using time-to-discontinuation, with log-rank testing for comparisons. Cox proportional hazards regression models identified baseline predictors of discontinuation.</p><p><strong>Results: </strong>A total of 178 patients (64.6% female) were included. The overall DRR for secukinumab was 64%, with the highest retention rate of 78% at 1 year. Discontinuation reasons included secondary inefficacy (57.8%), primary inefficacy (25%), and adverse events (17.2%), with infections being the most common adverse event. Higher body mass index (BMI) (HR 1.07, 95% CI: 1.02-1.12, p=0.010) and previous treatments (HR 1.34, 95% CI: 1.03-1.73, p=0.030) predicted long-term discontinuation. For 12-month discontinuation, peripheral phenotype (HR 4.28, 95% CI: 1.26-14.48, p=0.019) and prior biologic/targeted synthetic therapies (HR 1.76, 95% CI: 1.24-2.51, p=0.002) were predictors, while axial involvement was protective (HR 0.37, 95% CI: 0.17-0.83, p=0.016).</p><p><strong>Conclusions: </strong>Secukinumab demonstrates sustained effectiveness in SpA patients, with a significant proportion maintaining therapy over time. Retention is influenced by BMI, prior treatments, and disease phenotype, suggesting that outcomes may be optimised through tailored patient selection and early intervention.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144636283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of fasinumab in the treatment of osteoarthritis.","authors":"Haiyang Kou, Bo Chen","doi":"10.55563/clinexprheumatol/6fd0dc","DOIUrl":"https://doi.org/10.55563/clinexprheumatol/6fd0dc","url":null,"abstract":"<p><strong>Objectives: </strong>The aim of this meta-analysis and systematic review was to evaluate the clinical efficacy and safety of fasinumab in the treatment of osteoarthritis.</p><p><strong>Methods: </strong>RevMan 5.4 was utilised to conduct a meta-analysis after relevant data on randomised controlled trials of therapeutic interventions for patients with osteoarthritis were gathered from literature databases such as PubMed, Embase, Web of Science, and the Cochrane Library.</p><p><strong>Results: </strong>A total of 7 randomised controlled studies were included, including 32407 patients with osteoarthritis. Meta-analysis showed that compared with the control group, fasinumab intervention yielded more benefit, Western Ontario and McMaster Universities Osteoarthritis (WOMAC) pain (3 mg, week 8) (MD = -0.88, 95% CI [-1.22 to -0.53]; Z=5.04; p<0.00001), WOMAC pain (3 mg, week 16) (MD = -0.72, 95% CI [-1.34 to -0.10]; Z=2.27; p=0.02), WOMAC function (3 mg, week 8) (MD = -1.02, 95% CI [-1.36 to -0.69]; Z=6.05; p<0.00001) and WOMAC function (3 mg, week 16) (MD = -0.97, 95% CI [-1.35 to -0.59]; Z=4.98; p<0.00001).</p><p><strong>Conclusions: </strong>Fasinumab is a monoclonal antibody medication used to treat osteoarthritis and lessen pain. Fasinumab enhanced scores on the WOMAC function, WOMAC pain subscale, and numerical rating scale. Naturally, one cannot overlook the restrictions or difficulties brought on by limited sample sizes and demographic variety. Future research should promote the inclusion of bigger populations and larger sample sizes in order to develop an osteoarthritis treatment that is both affordable and effective.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144636339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vision-related quality of life in spondyloarthritis patients with acute anterior uveitis on golimumab: the GO-VISION study.","authors":"Inês Leal, Ana Teresa Melo, Carolina Ochôa Matos, Catarina Ferreira, Catarina Tenazinha, Cláudia Vaz, Eduardo Dourado, Fernando Pimentel, Filipe Cunha Santos, Henrique Fernandes, Joana Fonseca Ferreira, Manuel Silvério-António, Margarida Faria, Marta Guedes, Miguel Cordeiro, Miguel Santos, Nikita Khmelinskii, Patrícia José, Patrícia Pinto, Rafael Barão, Sara Dinis, Sofia Mano, Sofia Fonseca, Carlos Marques-Neves, Elsa Vieira-Sousa, João Eurico Fonseca","doi":"10.55563/clinexprheumatol/adr1j3","DOIUrl":"https://doi.org/10.55563/clinexprheumatol/adr1j3","url":null,"abstract":"<p><strong>Objectives: </strong>Acute anterior uveitis (AAU) associated with spondyloarthritis (SpA) is a common extra-articular manifestation, significantly impacting the health-related quality of life (HRQoL). The GO-VISION aimed to evaluate the effects of GOL on visual related (VR) and HRQoL, as well as health-related work productivity (HRWP), in individuals diagnosed with SpA and a history of SpA-AAU.</p><p><strong>Methods: </strong>This prospective, multicentre study included 20 SpA patients with recent SpA-AAU, treated with GOL and followed for 48 weeks. Data from the 2 years before and 48 weeks after GOL initiation were analysed to assess flare rates. QoL was evaluated using three standardised questionnaires: the National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25), the Short-Form 36 questionnaire (SF-36), and the EuroQol five-dimension scale questionnaire (EQ-5D). Additionally, the impact on HRWP was also studied. The differences between baseline, 24 and 48 weeks were assessed using a one-way repeated measures ANOVA.</p><p><strong>Results: </strong>Among 20 patients (55% male, 75% tumour necrosis factor-inhibitors (TNFi)-naive, mean age 45.2), AAU flares decreased from 50 in 2 years pre-GOL to 2 during treatment, reducing the incidence rate from 1.82 to 0.10 per 100 patient-years (p<0.01). Significant improvements were seen in NEI VFQ-25 total score (71.85-90.10), EQ index (0.74-0.89), SF-36 physical/mental scores (39.89/49.95 to 60.09/65.86), and hours lost to uveitis (4 to 0; all p<0.02). Two patients experienced mild TNFi-related adverse events.</p><p><strong>Conclusions: </strong>GO-VISION suggests the effectiveness of GOL in preventing SpA-AAU flares, improving HRQoL, and enhancing productivity, highlighting the importance of patient-reported outcomes.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144636292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disease activity and quality of life in patients with systemic lupus erythematosus: a validation study using the SLE-DAS.","authors":"Fung Lam, Kar Li Chan, Chi Hung To, Chi Chiu Mok","doi":"10.55563/clinexprheumatol/1n8j8d","DOIUrl":"10.55563/clinexprheumatol/1n8j8d","url":null,"abstract":"<p><strong>Objectives: </strong>To study the relationship between disease activity and quality of life (QoL) in patients with systemic lupus erythematosus (SLE) using the SLE disease activity score (SLE-DAS).</p><p><strong>Methods: </strong>Consecutive patients fulfilling the ACR/SLICC criteria for SLE were recruited. Participants were asked to complete the validated Chinese version of the LupusPRO for QoL evaluation before disease activity assessment by SLE-DAS, SLE disease activity index (SLEDAI)-2K and Physician Global Assessment (PGA). Correlation between disease activity and LupusPRO scores, and the effect of SLE-DAS remission on QoL was studied. Patients with active SLE at baseline, defined as a PGA≥0.5, were re-evaluated after 6 months. The change in LupusPRO score was correlated with the change in SLE-DAS.</p><p><strong>Results: </strong>A total of 510 patients were studied (92.9% women; age 48.6 ±13.3 years). At baseline, SLE-DAS remission (score ≤2.08), mild (2.08-7.64) and moderate/high disease activity (>7.64) was present in 364(71.3%), 75(14.7%) and 71(13.9%) patients, respectively. SLE-DAS index-based remission (score ≤2.08 and prednisone ≤5 mg/day) was achieved in 337(66.1%) patients. SLE-DAS correlated significantly with SLEDAI-2K and PGA (rho 0.92 and 0.62, respectively; p<0.01 in both). Patients with SLE-DAS index-based remission reported a significantly higher LupusPRO health-related (HR) QoL score compared to those without (76.8 ±16.2 vs. 69.0 ±16.8; p<0.01). A total of 139 patients with PGA ≥0.5 at baseline were reassessed at month 6: 77(55.4%) patients had improvement in SLE-DAS and 61(43.9%) patients achieved SLE-DAS index-based remission. The change in SLE-DAS was significantly associated with an improvement in LupusPRO HRQoL score (rho -0.30; p<0.01).</p><p><strong>Conclusions: </strong>SLE-DAS remission was associated with better QoL in patients with SLE. Reduction in SLE-DAS over time correlates significantly with improvement in health-related QoL.</p>","PeriodicalId":10274,"journal":{"name":"Clinical and experimental rheumatology","volume":" ","pages":"1227-1234"},"PeriodicalIF":3.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143647410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}